Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials - 08/03/25
on behalf of the
STREAM-2 Investigators
Highlights |
• | The STREAM-1 trial demonstrated similar outcomes with a PI strategy compared to primary PCI (PPCI) in STEMI patients presenting <3 hours of symptom onset and unable to undergo timely cardiac catheterization within 1 hour. |
• | However, an excess of intracranial hemorrhage (ICH) in those ≥75 years receiving PI treatment was observed early in the trial prompting a dose reduction amendment of tenecteplase (TNK) to half-dose after which no further ICH occurred. |
• | An analysis of STREAM-1 and STREAM-2 patients 60 to <75 years, found similar ST resolution and TIMI-3 patency with both half- and full-dose PI strategies with PI treatment (irrespective of TNK dose). These findings were also at least comparable than that achieved after their PPCI comparators. |
• | Whereas the risk of ICH with half-dose PI treatment was 2.1% compared to 1.5% with full-dose PI therapy, there was substantially less major (non-ICH) bleeding. Clinical outcomes were similar to those with their respective within trial PPCI comparators. |
ABSTRACT |
Background |
Previous studies indicate a safety risk with full-dose TNK in elderly patients. In a study of patients ≥60 years STREAM-2 (STrategic Reperfusion Early After Myocardial infarction-2), a pharmaco-invasive (PI) strategy with half-dose TNK was similar (in efficacy and safety) to primary percutaneous coronary intervention (PPCI) in ST-elevation myocardial infarction (STEMI) patients presenting <3 hours. While no treatment difference ± 75 years was observed, the role of this half-dose PI strategy in patients <75 years is unknown. In this comparison of STEAM-1 and -2, we analyzed PI strategies with full-dose (STREAM-1) versus half-dose TNK (STREAM-2) to evaluate their relative efficacy and safety in this younger STEMI cohort.
Methods |
We evaluated patients 60 to <75 years from STREAM-1 and STREAM-2 receiving PI treatment versus PPCI for their resolution of ST-elevation after fibrinolysis and angiography, primary efficacy composite of 30-day all-cause death, myocardial infarction, heart failure, and shock, and safety events.
Results |
Among 1103 patients, 327 received a full-dose PI strategy (STREAM-1), 289 a half-dose PI strategy (STREAM-2) and 487 PPCI (338 in STREAM-1; 149 in STREAM-2). Half- compared to full-dose TNK resulted in similar proportions of patients achieving ST resolution ≥50% (71.2% vs 68.7%, P = .519): their ICH risks were 2.1% vs 1.5%, P = .605 respectively). Following angiography, PI patients had nominally better ST resolution ≥50% compared to their PPCI counterpart (STREAM-1: 87.7% vs. 83.2%, P = .120; STREAM-2: 88.2% vs. 81.0%, P = .048) with similar primary composite outcome at 30 days (STREAM-1: 14.4% vs. 16.3%, 0.90 [0.62, 1.31]; STREAM-2: 9.0% vs 8.1%, 1.29 [0.64, 2.61]). Major (non-ICH) bleeding markedly declined in STREAM-2 compared to STREAM-1 in both treatment groups (STREAM-1: 7.1% vs. 6.0%; STREAM-2: 0.3% vs. 0.7%).
Conclusions |
In STEMI patients 60 to <75 years presenting within 3 hours of symptoms, half-dose PI treatment appears as efficacious as a full-dose PI strategy with a low systemic bleeding risk. Half-dose PI treatment deserves consideration when timely PPCI is not attainable in this important STEMI sub-group.
Clinicaltrials.gov registration numbers |
NCT00623623, NCT02777580.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Abbreviations : STREAM, ICH, STEMI, PPCI, PI, RR, ECG, TIMI, CABG, TRIANA, ESC
Mappa
Vol 284
P. 20-31 - Giugno 2025 Ritorno al numero
Articolo precedente
- The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design
- Richard P. Whitlock, Patrick M. McCarthy, Marc W. Gerdisch, Basel Ramlawi, John H. Alexander, Ibrahim Sultan, David Z. Rose, Jeffrey S. Healey, Yashasvi Awasthi Sharma, Emilie P. Belley-Côté, Stuart J. Connolly
- Impact of a clinical atrial fibrillation risk estimation tool on cardiac rhythm monitor utilization following acute ischemic stroke: A prepost clinical trial
- Jeffrey M. Ashburner, Reinier W.P. Tack, Shaan Khurshid, Ashby C. Turner, Steven J. Atlas, Daniel E. Singer, Patrick T. Ellinor, Emelia J. Benjamin, Ludovic Trinquart, Steven A. Lubitz, Christopher D. Anderson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?